Correspondence 0001493152-24-036171 from Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD.
Date: Sept. 13, 2024 · CIK: 0001962011 · Accession: 0001493152-24-036171
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-274805
Letter
Re: Kairos Pharma, Ltd.
September 13, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
F Street, N.E.
Washington, D.C. 20549-3720
Attention: Messrs. Dillon Hagius and Tim Buchmiller
Withdrawal of Acceleration Request - Registration Statement on Form S-1
File No. 333-274805
Ladies and Gentlemen,
Kairos Pharma, Ltd. (the “Company”) hereby withdraws its request to accelerate the effectiveness of the above-referenced Registration Statement submitted by letter via EDGAR dated September 9, 2024. The Company will file a separate request to accelerate the effectiveness of the Registration Statement.
Please contact Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Company, if you have any questions or concerns regarding this matter.
Very
truly yours,
KAIROS
PHARMA, LTD.
Show Raw Text
CORRESP
1
filename1.htm
September
13, 2024
Via
EDGAR
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F Street, N.E.
Washington,
D.C. 20549-3720
Attention:
Messrs. Dillon Hagius and Tim Buchmiller
Re:
Kairos
Pharma, Ltd.
Withdrawal
of Acceleration Request - Registration Statement on Form S-1
File
No. 333-274805
Ladies
and Gentlemen,
Kairos
Pharma, Ltd. (the “Company”) hereby withdraws its request to accelerate the effectiveness of the above-referenced Registration
Statement submitted by letter via EDGAR dated September 9, 2024. The Company will file a separate request to accelerate the effectiveness
of the Registration Statement.
Please
contact Megan J. Penick, Esq. of Dorsey & Whitney LLP, counsel for the Company, if you have any questions or concerns regarding this
matter.
Very
truly yours,
KAIROS
PHARMA, LTD.
By:
/s/
John S. Yu
John
S. Yu, M.D.
Chief
Executive Officer
cc:
Megan
J. Penick, Esq.
Dorsey
& Whitney LLP